R&D channel feed – Endpoints News

R&D channel feed

After a handful of stumbles, argenx doubles down on pipeline-in-a-product strategy as it pitches investors

11 months ago

A teenager faced constant seizures. Could a drug developed just for him stop them?

11 months ago

Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2 study this year

11 months ago

Revolution Medicines' RAS inhibitor shows promise in early-stage pancreatic cancer trial

11 months ago

Updated: Lexeo Therapeutics' gene therapy shows potential for Friedreich's ataxia cardiomyopathy with early data

11 months ago

Lilly says lupus drug dropped from pipeline failed to show efficacy

11 months ago

Indivior axes schizophrenia drug and shrinks revenue guidance

11 months ago

Immutep’s LAG-3 drug scores in Phase 2b head and neck cancer test

11 months ago

Pfizer presses forward with once-daily GLP-1 pill in long-awaited move

11 months ago

Ipsen takes on another ADC, this time from a China-based biotech

11 months ago

AbbVie CSO Tom Hudson to retire, replaced by medical chief

12 months ago

In less-studied female mice, scientists find hormone that could lead to new bone disease treatments

12 months ago

Amgen shelves early-stage bispecific T cell engager

12 months ago

Six big R&D questions for Pfizer as science chief Dolsten exits

12 months ago

UniQure trumpets mid-stage data for Huntington's disease gene therapy

12 months ago

Chinese drugmakers still lag in R&D depth despite outpacing Europeans in new launches

12 months ago

Lilly bests Novo Nordisk in observational study of GLP-1 drugs

12 months ago

Infections are major cause of non-relapse deaths after CAR-T cell therapy, study shows

12 months ago

HilleVax's stock tumbles after Phase 2b norovirus vaccine fails in infants

12 months ago

Ideaya showcases proof-of-concept data in a boost to synthetic lethality play

12 months ago

With cash expected to run dry, Inventiva ramps up search for funding

12 months ago

Roche’s TIGIT drug tiragolumab flunks another Phase 3 lung cancer test

Last year

Apollomics plans to lay off staff, narrow focus for lung cancer trial

Last year

Moderna wins $176M BARDA award to finance bird flu work

Last year

First page Previous page 40 41 424344 45 46 Next page Last page